ALVO — Alvotech
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1898416 ·
Last close
$5.25
Market Cap
$1.87B
52W High
$5.36
52W Low
$2.94
ADV30
933,464
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 105,865,000 | 59,778,000 | 9,674,000 | 1,030,000 | 1,421,168,000 | 63,832,000 | 1,703,480,000 |
| Dec 2025 | 166,573,000 | 105,293,000 | 48,255,000 | -108,547,000 | 1,487,099,000 | 172,359,000 | 1,771,586,000 |
| Sep 2025 | 113,744,000 | 78,738,000 | 1,313,000 | -5,252,000 | 1,409,178,000 | 42,848,000 | 1,585,941,000 |
| Jun 2025 | 173,239,000 | 99,414,000 | 18,057,000 | 32,038,000 | 1,392,754,000 | 151,452,000 | 1,566,082,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-123,175,000
Investing CF
$-130,015,000
Financing CF
$275,704,000
CapEx
$-118,954,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.35
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,408,760,000
Inventory
$228,017,000
Receivables
$133,054,000
ST Investments
—
EBIT TTM
$186,051,000
Pretax Income TTM
$43,913,000
Interest Exp TTM
$142,138,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$494,608,000
EBITDA
$75,733,000
Free Cash Flow
$-123,130,128
Enterprise Value
$3,182,324,480
Total Cash
$142,750,000
Total Debt
$1,451,784,960
Shares Out
356,817,038
Trailing EPS
$-0.74
Book Value
$-0.91
ROE
—
ROA
2.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 586,321,000 | 78,207,000 | 27,919,000 | 1,487,099,000 | 1,771,586,000 | — | -50,197,000 |
| Dec 2024 | 489,682,000 | 69,644,000 | -231,864,000 | 1,221,400,000 | 1,634,171,000 | — | -236,843,000 |
| Dec 2023 | 91,434,000 | -354,860,000 | -551,731,000 | 950,090,000 | 1,882,583,000 | — | -312,185,000 |
| Dec 2022 | 83,029,000 | -346,442,000 | -513,580,000 | 828,443,000 | 1,392,859,000 | — | -312,389,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.23
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMCR | Immunocore Holdings plc | $1.89B | $36.61 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.95B | $5.97 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.74B | $3.25 | — |
| VIR | Vir Biotechnology, Inc. | $1.68B | $9.91 | — |
| MAZE | Maze Therapeutics, Inc. | $1.64B | $29.60 | — |
News headlines (Yahoo Finance, 1h cache)
Alvotech (ALVO) Gets New ‘Buy’ Reco. Should Investors Follow?
2026-08-24 23:53 · Yahoo
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
2026-08-21 13:00 · Yahoo
Alvotech Q2 Earnings Call Highlights
2026-08-20 14:02 · Yahoo
Alvotech Q2 2026 Earnings Call Summary
2026-08-20 12:30 · Yahoo
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates
2026-08-19 21:45 · Yahoo
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
2026-08-19 20:30 · Yahoo
Alvotech announces successful closure of FDA inspection of manufacturing facility
2026-07-29 13:25 · Yahoo
Alvotech (ALVO) Stock May Be Undervalued Following Its $125 Million Offering
2026-07-02 20:11 · Yahoo
Alvotech’s US$240 Million Capital Boost Might Change The Case For Investing In Alvotech (ALVO)
2026-07-02 10:09 · Yahoo
Alvotech further strengthens liquidity by securing term loan facility of $75 million
2026-07-01 08:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.